CN118852182B - A porphyrin-chrysin conjugate and its synthesis method and application - Google Patents
A porphyrin-chrysin conjugate and its synthesis method and applicationInfo
- Publication number
- CN118852182B CN118852182B CN202410810674.1A CN202410810674A CN118852182B CN 118852182 B CN118852182 B CN 118852182B CN 202410810674 A CN202410810674 A CN 202410810674A CN 118852182 B CN118852182 B CN 118852182B
- Authority
- CN
- China
- Prior art keywords
- chrysin
- porphyrin
- conjugate
- reaction
- conjugate according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
- A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开了一种类卟啉‑白杨素偶合物及其合成方法和应用，属于药物合成技术领域。将类卟啉(如焦脱镁叶绿酸a)与白杨素通过酯化反应或碳碳双键加成反应进行偶联，得到具有光动力和化疗双重生物活性的类卟啉‑白杨素偶合物，可用于制备抗肿瘤药物。
The present invention discloses a porphyrin-like chrysin conjugate, its synthesis method, and application, belonging to the field of pharmaceutical synthesis technology. A porphyrin-like chrysin conjugate (such as pyropheophorbide a) is coupled with chrysin through an esterification reaction or a carbon-carbon double bond addition reaction to obtain a porphyrin-like chrysin conjugate with dual photodynamic and chemotherapeutic biological activities, which can be used to prepare anti-tumor drugs.
Description
Technical Field
The invention relates to a porphyrin-like chrysin conjugate and a synthesis method thereof, and also relates to application of the porphyrin-like chrysin conjugate in preparation of an anti-tumor agent for photodynamic therapy combined chemotherapy, belonging to the technical field of drug synthesis.
Background
Cancer remains a major cause of abnormal death in humans in the world, and malignant tumors are severely threatening the life and health of humans. Although the current surgical excision, radiation therapy, chemotherapy and immunotherapy have certain effects, the traditional Chinese medicine composition also has the problems of large traumas, large toxic and side effects, easy recurrence of tumors and the like.
Photodynamic therapy (photodynamic therapy, PDT) is an emerging high-efficiency treatment modality that uses lasers to intersystem cross and rapidly form triplet excited states of photosensitizers enriched in lesions, transferring energy to ground-state oxygen (3O2) to produce cytotoxic singlet oxygen (1O2). Therefore, the upper PDT has the advantages of low toxicity, small wound, good selectivity and the like. PDT has been applied to the treatment of skin cancer, squamous cell carcinoma, prostate cancer, breast cancer, cervical cancer, lung cancer, and many other cancers.
The photodynamic therapy-chemotherapy combined anti-tumor can exert the dual effects of photodynamic therapy and chemotherapy under the illumination, enhance the killing capacity of cancer cells, weaken the side effect of chemotherapy drugs on human bodies, and have great significance and value in research.
Chrysin is a flavonoid compound and has strong anti-tumor effect on breast cancer, cervical cancer, glioblastoma, esophageal cancer, colon cancer, prostatic cancer and the like in-vitro researches. However, the chemotherapy drugs such as chrysin generally have the problems of low bioavailability or large toxic and side effects in use. The porphyrin compound has a macrocyclic conjugated structure, is the most common photosensitizer, and has the advantages of easy accumulation in tumor focus, low cytotoxicity, strong absorption around a near infrared window, high singlet oxygen production rate and the like.
Chinese patent (CN 109912607A) discloses a novel porphyrin-chrysin derivative, which takes chemically synthesized hydroxy porphyrin as a matrix, dibromoalkane with different carbon atoms as a linking chain, and coupling chrysin phenolic hydroxyl and porphyrin phenolic hydroxyl in an ether bond mode to obtain the novel anti-tumor compound, but the porphyrin compound contains a symmetrical skeleton structure, the absorption wavelength of the porphyrin compound in a Q section is relatively smaller, and the porphyrin compound is mainly coupled in a bonding mode with good stability, so that a carrier and an anti-tumor drug are difficult to be released in cancer cell degradation.
Disclosure of Invention
Aiming at the defects existing in the prior art, the invention aims to provide a porphyrin-like chrysin conjugate, which takes porphyrin-like with photosensitive property as a carrier, chrysin with anticancer activity as a chemotherapeutic drug, and the conjugate of the porphyrin-like chrysin and chrysin can be used as an anticancer drug combining photodynamic and chemotherapy after being absorbed in visible light of 400-750 nm.
The second purpose of the invention is to provide a novel synthesis method of porphyrin-like-chrysin conjugate, which has the advantages of wide source of porphyrin-like adopted, mild condition, high coupling efficiency, high yield of target conjugate and contribution to mass production.
The third object of the invention is to provide an application of porphyrin-like chrysin conjugate, which has double biological activities of photodynamic and chemotherapy and can be applied as an anti-tumor drug.
The fourth object of the invention is to provide a preparation method of porphyrin-like material, which simplifies the obtaining process of pyropheophorbide a as raw material of porphyrin-like material, improves yield, and can reduce the synthesis cost of porphyrin-like chrysin conjugate.
In order to achieve the technical aim, the invention provides a porphyrin-like chrysin conjugate, which has the following characteristics that
Formula 1, formula 2, formula 3 or formula 4:
wherein, the
R 1 and R 3 are selected fromR is selected fromOr C 1～C10 alkyl, R 2、R8 and R 9 are independently selected from H,Or C 1～C10 alkyl;
R 4 and R 5 are selected from H or R 6 and R 7 are independently selected fromR 10、R11、R12 and R 13 are independently selected from H orAnd each of the formulas 1 to 4 at least comprises one
As a preferred embodiment, the porphyrin-like chrysin conjugate has the following structural formula:
The invention also provides a synthesis method of the porphyrin-chrysin-like conjugate, which comprises the following steps:
coupling carboxyl porphyrin-like compound with phenolic hydroxyl of chrysin via esterification reaction, or
Coupling vinyl porphyrin with phenolic hydroxyl of chrysin via indirect addition reaction, or
Coupling carboxyl and vinyl porphyrin-like compound with phenolic hydroxyl of chrysin through esterification and/or indirect addition reaction;
the porphyrin-like compound has a structure of formula 5, formula 6, formula 7, or formula 8:
wherein, the
R 15 and R 16 are selected fromR 0 is selected from alkyl of C 1～C10;
R 14、R17 and R 18 are independently selected from H or C 1～C10 alkyl.
As a preferable scheme, the esterification reaction is carried out for 12-24 hours at 0-25 ℃ by taking DCM as a solvent, taking 1-ethyl- (3-dimethylaminopropyl) carbodiimide hydrochloride and/or N, N' -dicyclohexylcarbodiimide as a condensing agent and taking 4-dimethylaminopyridine and/or 1-hydroxybenzotriazole as a catalyst. The solvent may also be selected from chloroform and Tetrahydrofuran (THF), but less effective than Dichloromethane (DCM). A preferred catalyst is 4-Dimethylaminopyridine (DMAP). The preferable reaction temperature is 15-25 ℃.
As a preferable scheme, the ratio of the carboxyl content in the carboxyl-containing porphyrin-like or carboxyl-and vinyl-containing porphyrin-like to the mass of the condensing agent, chrysin and catalyst is 1 (1.5-2): 0.5, and the feeding ratio of the condensing agent to the chrysin is the same.
As a preferable scheme, the indirect addition reaction comprises the steps of adding vinyl porphyrin or carboxyl and vinyl porphyrin with hydrogen bromide and then carrying out nucleophilic substitution reaction with chrysin.
As a preferable scheme, the condition of the addition reaction is that a mixed solution of hydrogen bromide and acetic acid is used as an addition reagent, and the reaction is carried out for 8-16 hours at the temperature of 0-25 ℃. The mixed solution of the hydrogen bromide and the acetic acid is 33 percent mixed solution of the hydrogen bromide and the acetic acid, and the mass concentration of the hydrogen bromide is 33 percent.
As a preferable scheme, the nucleophilic substitution reaction is carried out for 8-16 hours at 0-25 ℃ by taking K 2CO3 as an alkaline reagent and 18-crown ether-6 as a cosolvent.
The invention also provides application of the porphyrin-chrysin-like conjugate in preparing an antitumor agent for photodynamic therapy combined chemotherapy. The invention takes the esterification coupling product PPA-C of pyropheophorbide a (PPA) and chrysin (Chrysin) as an example to verify the photodynamic and chemotherapeutical dual anti-tumor effect of the pyropheophorbide on melanoma.
The invention also provides a preparation method of the porphyrin-like product, which comprises the steps of mixing silkworm excrement mud with an acid degradation solvent for acidolysis reaction, recovering acetic acid from the reaction mixture through reduced pressure distillation after acidolysis reaction is completed, pouring the reaction mixture into saturated saline water, and separating out a porphyrin-like crude product, wherein the acid degradation solvent consists of concentrated hydrochloric acid and acetic acid according to a volume ratio of 1:8-10, and the liquid-solid ratio of the acid degradation solvent to the silkworm excrement mud is 2.5-5 mL:1g. The acidolysis reaction is carried out at room temperature, and the reaction time is 8-16 hours.
The porphyrin-like compound can be derived from degradation products of chlorophyll a, for example, the porphyrin-like compound is obtained by acid degradation and extraction of silkworm excrement mud containing chlorophyll a as a raw material:
the acid degradation route of chlorophyll a is as follows:
Compound 1 and compound 2 are prepared from chlorophyll a by acid degradation, usually by diethyl ether hydrochloride, and the amount of hydrochloric acid used is usually 1-5 times of that of diethyl ether (reference document: chemical research of chlorophyll a degradation process in silkworm excrement, yao Jianzhong et al, chinese herbal medicine, 1999, (08): 568-571).
According to the invention, acetic acid is used for replacing diethyl ether, the proportion of hydrochloric acid used is greatly reduced (the volume ratio of hydrochloric acid to acetic acid is 1:8-10), most acetic acid can be recovered through reduced pressure rotary evaporation, and 10 times of cold saturated saline water is added into the residual acetic acid and hydrochloric acid, so that a chlorophyll a acid degradation crude product can be separated out.
Porphyrin-like compounds of the present invention are coupled to chrysin by esterification (illustrated by pyropheophorbide a):
According to the invention, EDCI is used as a dehydration condensing agent, DMAP is used as a nucleophilic catalyst, pyro-magnesium chlorophyllin a and chrysin are subjected to esterification coupling in DCM, the condition is mild, and as chrysin is insoluble in DCM, the byproducts of direct reaction of chrysin and the dehydration condensing agent are reduced, and the esterification coupling product with higher purity is obtained.
Porphyrin-like compounds are addition coupled with chrysin (illustrated by pyropheophorbide a methyl ester):
according to the invention, the addition coupling product of the chlorophyll a derivative and the chrysin is prepared by a two-step method, and the reaction is carried out at room temperature, so that the elimination reaction of the brominated porphyrin intermediate under alkaline conditions is reduced, the chrysin nucleophilic substitution product and the hydrolysis byproduct are obtained, and the raw material conversion rate is improved.
The molecular structure of the part of porphyrin-chrysin-like conjugate prepared by the invention is as follows:
Porphyrins of the present invention include carboxyl or vinyl groups such as chlorophyll-a acid-degrading derivatives, heme derivatives, and synthetic porphyrin compounds, including but not limited to the following:
compared with the prior art, the technical scheme of the invention has the beneficial technical effects that:
The porphyrin-like-chrysin conjugate provided by the invention takes porphyrin-like with photosensitive property as a carrier, chrysin with anticancer activity as a chemotherapeutic drug, particularly the conjugate of the porphyrin-chrysin and the chrysin can be absorbed in visible light of 400-750 nm and can be used as an anticancer drug combined with photodynamic therapy, and meanwhile, the porphyrin-like-chrysin conjugate can be bonded with chrysin by utilizing ester groups with biological activity, so that the porphyrin-like-chrysin conjugate has good stability outside cancer cells, and is easy to degrade and release the antitumor drug in the cancer cells.
The synthesis method of the porphyrin-like chrysin conjugate provided by the invention has the advantages of wide raw material sources, mild conditions, high coupling efficiency and high yield of the target conjugate, and is beneficial to large-scale production.
The synthesis method of the porphyrin-like raw material provided by the invention is simple, the yield is high, and the raw material cost of the porphyrin-like-chrysin conjugate is greatly reduced.
Drawings
FIG. 1 is a PPIX-C2 mass spectrometry detection (ESI +).
FIG. 2 is a TCPP-C4 mass spectrometry detection map (ESI +).
FIG. 3 is a TCPP-C3 mass spectrometry detection map (ESI +).
FIG. 4 is a TCPP-C2 mass spectrometry detection map (ESI +).
FIG. 5 is a mass spectrometric detection diagram (ESI +) of TCPP-C2 and TCPP-C1.
FIG. 6 is a schematic illustration of photodynamic and chemotherapeutic combination anti-tumor of porphyrin-like chrysin conjugates.
FIG. 7 is an ultraviolet visible light absorption spectrum of porphyrin-like chrysin conjugate in DCM.
FIG. 8 is an infrared spectrum of PPA and CHRYSIN with PPA-C.
FIG. 9 is a photograph showing the anti-melanoma activity test (cell live/dead staining analysis) of PPA-C and a control thereof.
FIG. 10 is an ultraviolet-visible absorption spectrum of PPA, NPC, PPA-C anti-melanoma test sample (PBS solution).
Detailed Description
In order to make the solution of the present invention clearer, technical advantages of the solution of the present invention are further highlighted, the following description is provided with reference to specific embodiments.
The chlorophyll-a derivative used in the present invention is prepared by the following method.
The methyl pyropheophorbide a and the hexyl ether derivatives thereof are prepared from silkworm excrement mud.
Example 1
Preparation of crude drug pyropheophorbide a (PPA):
50g of silkworm excrement mud is taken, 160mL of acetic acid is added for dissolution, 20mL of concentrated hydrochloric acid is added under ice bath, stirring is continued for more than 12h at room temperature, suction filtration is carried out, the filtrate is decompressed and distilled out most of acetic acid, 150mL of cold saturated saline water is added, standing is carried out for 1h, filtration is carried out, filter cakes are dried, crude products are subjected to silica gel column chromatography by taking methanol=10:1 as developing agents according to the volume ratio of dichloromethane, 489mg of pyropheophorbide a (PPA) is obtained, the purity is detected by High Performance Liquid Chromatography (HPLC), 178mg of purple rod-shaped crystals with metallic luster is obtained through ethanol-petroleum ether recrystallization, and the purity is detected by High Performance Liquid Chromatography (HPLC) to be more than 95%.
PPA molecular structure characterization ：1H-NMR(400MHz,DMSO-d6,ppm)δ12.08(s,1H,37-OH),9.66(s,1H,10-CH),9.40(s,1H,5-CH),8.88(s,1H,20-CH),8.16-8.23(dd,1H,26-CH),6.35-6.4(dd,1H,27-CH),6.18-6.22(dd,1H,27'-CH),5.09-5.24(q,2H,33-CH2),4.56-4.61(m,1H,18-CH),4.30-4.33(m,1H,17-CH),3.64-3.69(q,2H,29-CH2),3.59(s,3H,31-CH3),3.43(s,3H,28-CH3),3.19(s,3H,25-CH3),2.53-2.60(m,2H,35-CH2),2.29-2.35(m,H,34-CH),2.07-2.15(m,H,34'-CH),1.77-1.79(d,3H,38-CH3),1.59-1.63(t,3H,30-CH3),0.21(s,1H,21-NH),-2.00(s,1H,23-NH).
MS(ESI+)m/z:535.27[M+H]+(100%)。
Example 2
Preparation of crude drug pyropheophorbide a methyl ester (MPPA):
50g of silkworm excrement mud is taken, 200mL of methanol is added for dissolution, 5mL of concentrated sulfuric acid is added under ice bath while stirring, stirring is continued for more than 12 hours at room temperature, most of methanol is distilled off under reduced pressure, 100mL of ultrapure water is added, the pH is regulated to 4-6 by using a concentrated NaOH solution, diatomite is used for filtration assistance, after a filter cake is dried, dichloromethane is used for washing, and filtrate is distilled under reduced pressure to obtain black sticky matter. Dissolving with a small amount of ethyl acetate, adding petroleum ether 10 times of ultrasonic treatment for 1-5min, and suction filtering to obtain black solid with metallic luster 4.5g (containing methyl pheophorbide a and methyl pyropheophorbide a).
Dissolving the crude product with 80mL of pyridine, protecting with argon, heating and refluxing for 8h, removing methoxycarbonyl (-COO CH 3) at position 33, evaporating pyridine under reduced pressure, performing ultrasonic treatment with dilute hydrochloric acid with pH=1 for 1min, extracting with dichloromethane, washing organic phase with water, performing rotary evaporation under reduced pressure to obtain 3.8g of pyropheophorbide a methyl ester crude product, and detecting content by High Performance Liquid Chromatography (HPLC) to 13.82%. And performing silica gel column chromatography by taking ethyl acetate and petroleum ether=1:2 as developing agents to obtain refined pyropheophorbide a methyl ester 504mg. High Performance Liquid Chromatography (HPLC) assay purity 91.7%.
MPPA molecular structure characterization ：1H-NMR(400MHz,CDCl3,ppm)δ9.52(s,1H,10-CH),9.40(s,1H,5-CH),8.56(s,1H,20-CH),7.97-8.05(dd,1H,26-CH),6.26-6.31(dd,1H,27-CH),6.16-6.19(dd,1H,27'-CH),5.09-5.29(q,2H,33-CH2),4.46-4.52(m,1H,18-CH),4.29-4.31(m,1H,17-CH),3.68-3.73(q,2H,29-CH2),3.68(s,3H,37-OCH3),3.61(s,3H,31-CH3),3.41(s,3H,28-CH3),3.21(s,3H,25-CH3),2.53-2.72(m,2H,35-CH2),2.25-2.36(m,H,34-CH2),1.80-1.82(d,3H,38-CH3),1.68-1.72(t,3H,30-CH3),0.46(s,1H,21-NH),-1.68(s,1H,23-NH).
MS(ESI+)m/z:549.29[M+H]+(100%)。
Example 3
Preparation of crude drug pyropheophorbide a-hexyl ether (HPPA):
Taking 100mg of pyropheophorbide a (PPA), dissolving the pyropheophorbide a (PPA) with 10mL of anhydrous dichloromethane, adding 1mL of 33% HBr-CH 3 COOH solution, carrying out ice bath 0-15 ℃ for reaction for 12h, decompressing, steaming to remove solvent and acetic acid, drying by argon, adding 10mL of anhydrous dichloromethane for redissolving, and adding 0.5mL of n-hexylether. And (3) reacting for 12 hours at room temperature (15-20 ℃), removing the solvent under reduced pressure, dissolving the HPPA sodium salt by using ethanol containing a small amount of NaOH, adding excessive petroleum ether to separate out HPPA sodium salt, and adjusting the pH after water dissolution to obtain an HPPA crude product. Chromatography on methylene chloride and methanol=15:1 silica gel gave 58mg of pyropheophorbide a-hexyl ether as pure product. High Performance Liquid Chromatography (HPLC) assay purity 93.9%.
Characterization of HPPA molecular Structure ：1H-NMR(400MHz,CDCl3,ppm)δ9.76(s,1H,10-CH),9.48(s,1H,5-CH),8.50(s,1H,20-CH),5.86-5.91(q,1H,26-CH),5.09-5.29(q,2H,33-CH2),4.45-4.48(m,1H,18-CH),4.30-4.32(m,1H,17-CH),3.68-3.72(q,2H,29-CH2),3.65(s,3H,37-OCH3),3.61(s,3H,31-CH3),3.55-3.59(t,2H,38-CH2),3.36(s,3H,28-CH3),3.25(s,3H,25-CH3),2.57-2.70(m,2H,35-CH2),2.295-2.35(m,H,34-CH2),2.09-2.11(d,3H,27-CH3),1.28-1.71(d,37-CH3,30-CH3,39-CH2,40-CH2,41-CH2,42-CH2),0.74-0.78(t,3H,43-CH3),-1.68(s,1H,23-NH).
MS(ESI+)m/z:637.38[M+H]+(100%)。
Preparation of chlorophyll a derivative and chrysin conjugate:
Example 4
Preparation of the esterification coupling product (PPA-C) of pyropheophorbide a (PPA) and chrysin (chrysin):
Into a 25mL flask, PPA53.4mg (0.1 mmol), chrysin 38.1mg (0.15 mmol), EDCI 28.8mg (0.15 mmol), DMAP 6.1mg (0.05 mmol) and 10mL of anhydrous Dichloromethane (DCM) were added and the reaction was carried out at room temperature in the dark for about 24h. The solvent was distilled off under reduced pressure, washed with 1% dilute hydrochloric acid and then with ultrapure water, extracted with dichloromethane, the organic phase was removed by rotary evaporation under reduced pressure to give crude PPA-C esterified product, which was subjected to column chromatography on silica gel with a volume ratio of developing solvent to dichloromethane: methanol=20:1 to give 66.3mg of PPA-C esterified product in 85% yield.
PPA-C molecular structure characterization ：1H-NMR(400MHz,CDCl3,ppm)δ12.46(s,1H,-OH),9.44(s,1H,10-CH),9.36(s,1H,5-CH),8.59(s,1H,20-CH),7.98-8.05(dd,1H,26-CH),7.77(s,1H),7.75(s,1H),7.50-7.57(m,3H),6.60(s,1H),6.28-6.33(dd,1H,27-CH2),6.17-6.22(dd,1H,27'-CH2),6.13(dd,1H),5.13-5.34(q,2H,33-CH2),4.55-4.60(m,H,18-CH),4.42-4.44(m,H,17-CH),3.66(s,3H,31-CH3),3.61-3.65(q,2H,29-CH2),3.43(s,3H,28-CH3),3.20(s,3H,25-CH3),2.58-2.79(m,2H,35-CH2),2.44-2.51(m,2H,34-CH2),1.84-1.86(d,3H,37-CH3),1.66-1.70(t,30-CH3),0.42(s,1H,21-NH),-1.74(s,1H,23-NH).
MS(ESI+)m/z:771.32[M+H]+(100%)。
As can be seen by comparing the infrared absorption spectrum of the raw materials PPA and CHRYSIN and the esterified coupling product (PPA-C), the carboxyl O-H stretching vibration peak (3293 cm -1) of the raw material pyropheophorbide a (PPA) and the 7-position phenolic hydroxyl O-H stretching vibration peak (2632 cm -1) of Chrysin (CHRYSIN) disappear in the coupling product (PPA-C), and the rest characteristic peaks are basically matched.
Example 5
Preparation of the coupling product of pyropheophorbide a-hexyl ether (HPPA) and chrysin (chrysin) (HPPA-C):
into a 25mL round bottom flask was added 63.7mg (0.1 mmol) HPPA, chrysin 38.1mg (0.15 mmol), EDCI 38.4mg (0.2 mmol), DMAP 6.1mg (0.05 mmol), and 8mL of anhydrous Dichloromethane (DCM) was added and after ultrasonic dispersion, the reaction was carried out at room temperature in the dark for about 24h. The solvent was distilled off under reduced pressure, followed by washing with 1% dilute hydrochloric acid and ultrapure water, extraction with dichloromethane, removal of the organic phase by rotary evaporation under reduced pressure to give crude HPPA-C esterified product, which was subjected to column chromatography on silica gel with a volume ratio of developing solvent dichloromethane: methanol=30:1 to give 82mg of HPPA-C esterified product in 92% yield.
Characterization of HPPA-C molecular Structure ：1H-NMR(400MHz,CDCl3,ppm)δ12.52(s,1H,-OH),9.75(s,1H,10-CH),9.45(s,1H,5-CH),8.55(s,1H,20-CH),
7.77(s,1H),7.75(s,1H),7.46-7.55(m,3H),6.58(s,1H),6.38-6.39(d,1H),6.15(dd,1H),5.89-5.94(q,H,26-CH),5.12-5.32(q,2H,33-CH2),4.53-4.38(m,H,17-CH),4.40-4.43(m,H,18-CH),3.67-3.71(q,2H,29-CH2),3.64(s,3H,31-CH3),3.59-3.62(t,2H,38-CH2),3.39(s,3H,28-CH3),3.24(s,3H,25-CH3),2.68-2.78(m,2H,35-CH2),2.39-2.60(m,H,34-CH2),2.11-2.13(d,3H,27-CH3),1.84-1.86(d,37-CH3),1.72-1.76(m,39-CH2),1.66-1.70(t,30-CH3),1.35-1.41(m,6H,40,41,42-CH2),0.76-0.79(t,3H,43-CH3),0.42(s,1H,21-NH),-1.75(s,1H,23-NH).
MS(ESI+)m/z:873.42[M+H]+(100%)。
Example 6
Preparation of pyropheophorbide a methyl ester (MPPA) and chrysin (chrysin) indirect addition coupling product (MPPA-C):
MPPA 54.9mg (0.1 mmol) was taken and dissolved in 5mL of anhydrous dichloromethane, and then added
0.5Ml of 33% HBr-CH 3 COOH solution is reacted for 12 hours in ice bath at 0-15 ℃, the solvent and acetic acid are distilled off under reduced pressure, 50.8mg (0.2 mmol) of chrysin, 200mg of newly baked anhydrous K 2CO3, 200mg of 18-crown ether-6, 10mL of anhydrous tetrahydrofuran alkane are added after blowing dry, the reaction is carried out for 12 hours at room temperature (15-20 ℃), the solvent is removed under reduced pressure, after dissolving with dichloromethane, suction filtration is carried out on the filtrate, dilute hydrochloric acid with pH=1 is carried out on the filtrate, ultrapure water is used, the solvent is washed successively, the organic phase is distilled off in a rotary way to obtain purple black solid, the coupling product (MPPA-chrysin) is indirectly added with the coupling product (MPPA-chrysin) of the pyropheophorbide a methyl ester (MPPA) and the chrysin (chrysin) according to the volume ratio of petroleum ether: acetone=3:1, and the coupling product is obtained by indirect addition, and the yield is 32.5%.
Characterization of MPPA-C molecular structure:
1H-NMR(400MHz,CDCl3,ppm)δ12.56(s,0.5H,-OH),12.54(s,0.5H,-OH),9.66(s,0.5H,10-CH),9.65(s,0.5H,10-CH),9.50(s,0.5H,5-CH),9.49(s,0.5H,5-CH),8.55(s,1H,20-CH),7.61(s,1H),7.59(s,1H),7.31-7.41(m,3H),6.83-6.87(m,1H,26-CH),6.72-6.73(d,1H),6.64-6.65(t,1H),6.41(d,H),5.07-5.27(q,2H,34-CH2),4.42-4.48(m,H,17-CH),4.26-4.28(m,H,18-CH),3.67-3.73(q,2H,30-CH2),3.64(s,3H,38-CH3),3.58(s,3H,32-CH3),3.46(d,3H,29-CH3),3.33(s,3H,25),2.48-2.57(m,H,36-CH2),2.19-2.27(m,H,365-CH2),2.34-2.36(dd,2H,35-CH2),1.76-1.81(q,3H,39-CH3),1.68-1.72(m,3H,31-CH3),-1.85(s,1H,23-NH).
MS (ESI +)m/z:803.34.42[M+H]+ (100%) (MPPA-C and by-product mass spectrometry detection map).
Chrysin (chrysin) can also be coupled with protoporphyrin (PPIX) and tetra-carboxyphenyl porphyrin (TCPP) by esterification to give bifunctional products including, but not limited to, the following compounds.
Example 7
Preparation of an esterified conjugate of a polycarboxy porphyrin compound and chrysin:
56.3mg (0.1 mmol) of protoporphyrin (PPIX), 40.6mg (0.2 mmol) of N, N' -Dicyclohexylcarbodiimide (DCC) were taken, dissolved by ultrasound with 25mL of tetrahydrofuran, activated for 1h at room temperature, 6mg (0.05 mmol) of 4-Dimethylaminopyridine (DMAP), 50.8mg (0.2 mmol) of chrysin and a little pyridine were added, and after continuing the reaction for 12h, PPIX-C2 (FIG. 1) was detectable by mass spectrometry. The same method can be used for carrying out esterification coupling on tetra-carboxyl phenyl porphyrin and chrysin, and different coupling products are detected by mass spectrometry (figures 2-5).
Monocarboxylic porphyrin compounds, particularly chlorophyll a acid degradation products, such as pyropheophorbide a, are coupled with chrysin by Steglich esterification, EDCI is selected as condensing agent, DMAP is catalyst, residual EDCI and DMAP can be removed by dilute hydrochloric acid and water washing, and the chrysin is insoluble in DCM, so that excess chrysin can be separated by DCM. The PPA-C and PA-C obtained by the invention have the yield of HPPA-C higher than 80% and the purity higher than 90%.
Polycarboxyporphyrin compounds require the selection of a solvent such as THF which is still relatively large because of poor solubility in DCM, and require the selection of DCC as a condensing agent and DMAP catalysis and pyridine as a base because EDCI is insoluble in THF, thereby improving esterification efficiency.
The porphyrin compound vinyl and chrysin are subjected to indirect addition reaction, and intermediate bromoporphyrin is easy to hydrolyze, and elimination reaction is easy to occur in the presence of organic base such as triethylamine at the temperature of more than 30 ℃, so that the water content and the temperature of the upper raw material and the solvent have great influence on the yield and purity. The raw materials used in the invention are all dried for 48 hours by phosphorus pentoxide under vacuum, the solvent is anhydrous dichloromethane and anhydrous tetrahydrofuran, newly baked K 2CO3 is selected as alkali, 18-crown ether-6 is taken as cosolvent of alkali, and the indirect addition product of MPPA and chrysin is obtained after reaction for more than 12 hours at room temperature.
Example 8
Evaluation of anti-tumor cell Activity of porphyrin-chrysin conjugate Using PPA-C as an example:
the PPA-C anti-melanoma cell activity experiments are arranged into 10 groups of 3 parallel experiments. And the numbers 1 to 5 are illumination groups, and the numbers 6 to 10 do not illuminate. Wherein NPC represents a co-assembled nanoparticle of PPA and Chrysin.
| Numbering device | Medicine name | Conditions (conditions) |
| 1 | Blank control | Illumination (660 nm,0.1W/cm 2) |
| 2 | PPA | Illumination (660 nm,0.1W/cm 2) |
| 3 | Chrysin | Illumination (660 nm,0.1W/cm 2) |
| 4 | PPA-C | Illumination (660 nm,0.1W/cm 2) |
| 5 | NPC | Illumination (660 nm,0.1W/cm 2) |
| 6 | Blank control | Dark black |
| 7 | PPA | Dark black |
| 8 | Chrysin | Dark black |
| 9 | PPA-C | Dark black |
| 10 | NPC | Dark black |
PPA, chrysin, PPA-C and NPC of the medicine to be tested are configured according to the following method:
PPA 1mgPPA is weighed and dissolved in 1mLDMSO, the DMSO solution of 10 mu LPPA is diluted by 10mLPBS, and finally 100 mu LPBS diluted sample is added into 1mL of culture medium containing melanoma, and the final concentration is 0.19 mu mol/L.
And (3) the same principle:
Chrysin:0.5mg/1 mM LDMSO, 10. Mu.l/10 mM LPBS, 100. Mu.l/1 mL medium, 0.18. Mu. Mol/L.
PPA-C1.5 mg/1 mM LDMSO, 10. Mu.L/10 mM LPBS, 100. Mu.L/1 mL medium, 0.19. Mu. Mol/L.
Preparation of NPC:
1mg Chrysin is weighed and dissolved in 2mL of THF, 400 mu L is dripped into 10mL of 0.1M NaOH aqueous solution, 1mg of PPA is weighed and dissolved with 1mL of THF, 400 mu L is dripped into 10mL of 0.1M NaOH aqueous solution, the pH is adjusted to 6-7 by 1M hydrochloric acid under vigorous stirring, stirring is continued for 4h, and THF is removed by argon bubbling, so that NPC is obtained. After 250. Mu. LNPC was diluted with 10mLPBS, the 100. Mu. LPBS diluted sample was finally added to 1mL of melanoma-containing medium at a final concentration of 0.19. Mu. Mol/L.
In vitro anti-melanoma Activity assay of PPA-C:
First, melanoma cells were seeded into 24-well plates at a density of 5×10 3 cells/well and the plates were incubated for 24 hours. Then, the medium in each well was removed, 1mL of fresh medium and 100. Mu.L of the sample to be tested were added, and incubated for 4 hours. The substrate was irradiated with 660nm laser (0.1W/cm 2) for 5 minutes. Incubating for 3 hours, discarding the culture medium, digesting the cells with 100-150 mu L of pancreatin, collecting and centrifuging, washing off residual pancreatin with PBS, adding CALCEIN AM/PI detection working solution according to the instructions for use to perform live and dead cell staining (green labeling of live cells, red labeling of dead cells), incubating for 30 minutes in a dark place and imaging the melanoma cells by using an Olympus inverted fluorescence microscope.
The experimental results are shown in FIG. 9, and the chrysin has certain in vitro anti-melanoma activity under illumination or not at the same concentration (0.19 mu mol/L), and the activity under illumination is slightly strong. PPA shows its photodynamic anti-melanoma activity only under light, NPC is more potent than Chrysin and PPA, PPA-C shows very potent anti-melanoma activity under light and is much higher than NPC and PPA under equivalent conditions. The ultraviolet and visible light absorption spectrum analysis of the PPA, NPC and PPA-C to-be-detected samples is obtained, a part of the PPA DMSO solution is dispersed into the PBS buffer solution to form nano particles by self-assembly, and the Q section (650-750) of the PBS ultraviolet and visible light region has two absorption peaks which belong to the visible light absorption peaks of free PPA and PPA nano particles respectively. Whereas PPA-C, due to the absence of carboxyl groups, has poor self-assembly ability and exists mainly in the form of single molecules before entering cells. After entering the cell, PPA-C may be hydrolyzed by intracellular esterases, thereby releasing chrysin, which allows PPA-C to show a certain activity also in the absence of light. And PPA and NPC have limited number of cells due to the mutual encapsulation of molecules, so that the photodynamic activity of the PPA and NPC under illumination is weaker than that of PPA-C.
Therefore, the carboxyl porphyrin and chrysin esterified conjugate prepared by the invention has practical application value in the aspect of photodynamic therapy anti-tumor.
Claims (9)
1. A porphyrin-like chrysin conjugate is characterized by having a structural formula of formula 1:
1 (formula)
Wherein, the
R 1 is selected fromOr (b)R is selected fromOr C 1~C10 alkyl;
r 2 is selected from H, Or C 1~C10 alkyl;
and at least one of the formula 1 。
2. The porphyrin-like chrysin conjugate according to claim 1, which is characterized by having the following structural formula:
、 Or alternatively 。
3. A method for synthesizing porphyrin-like chrysin conjugate according to claim 1 or 2, characterized in that:
Coupling carboxyl porphyrin-like and phenolic hydroxyl of chrysin through esterification reaction to obtain the product;
Or alternatively
Coupling vinyl porphyrin-like and phenolic hydroxyl of chrysin through indirect addition reaction to obtain the coupling agent;
Or alternatively
Coupling carboxyl and vinyl porphyrin-like compound with phenolic hydroxyl of chrysin through esterification and/or indirect addition reaction;
the porphyrin-like compound has the structure of formula 5:
5 parts of
Wherein, the
R 15 is selected fromOr (b)R 0 is selected from alkyl of C 1~C10;
R 14 is selected from H or C 1~C10 alkyl, and R 15 is selected from When R 14 is not simultaneously selected from the alkyl groups of C 1~C10.
4. The method for synthesizing porphyrin-like chrysin conjugate according to claim 3, wherein the esterification reaction is carried out for 12-24 hours at 0-25 ℃ by using DCM as a solvent, 1-ethyl- (3-dimethylaminopropyl) carbodiimide hydrochloride and/or N, N' -dicyclohexylcarbodiimide as a condensing agent and 4-dimethylaminopyridine and/or 1-hydroxybenzotriazole as a catalyst.
5. The method for synthesizing a porphyrin-like-chrysin conjugate according to claim 4, wherein the ratio of the carboxyl content in the porphyrin-like compound containing carboxyl groups or the porphyrin-like compound containing carboxyl groups and vinyl groups to the amounts of the condensing agent, chrysin and catalyst is 1 (1.5-2): (0.4-0.6), and the feeding ratio of the condensing agent to chrysin is the same.
6. The method for synthesizing a porphyrin-chrysin-like conjugate according to claim 3, wherein the indirect addition reaction comprises the steps of adding hydrogen bromide to porphyrin-like containing vinyl or porphyrin-like containing carboxyl and vinyl, and then carrying out nucleophilic substitution reaction with chrysin.
7. The method for synthesizing porphyrin-like chrysin conjugate according to claim 6, wherein the condition of the addition reaction is that a mixed solution of hydrogen bromide and acetic acid is used as an addition reagent, and the reaction is carried out for 8-16 hours at 0-25 ℃.
8. The method for synthesizing porphyrin-like chrysin conjugate according to claim 6, wherein the nucleophilic substitution reaction is carried out for 8-16 hours at 0-25 ℃ under the condition that K 2CO3 is used as an alkali reagent and 18-crown ether-6 is used as a cosolvent.
9. The use of a porphyrin-like chrysin conjugate according to claim 1 or 2 for the preparation of a photodynamic therapy combined chemotherapy antitumor agent.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202410810674.1A CN118852182B (en) | 2024-06-21 | 2024-06-21 | A porphyrin-chrysin conjugate and its synthesis method and application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202410810674.1A CN118852182B (en) | 2024-06-21 | 2024-06-21 | A porphyrin-chrysin conjugate and its synthesis method and application |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN118852182A CN118852182A (en) | 2024-10-29 |
| CN118852182B true CN118852182B (en) | 2025-10-28 |
Family
ID=93161888
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202410810674.1A Active CN118852182B (en) | 2024-06-21 | 2024-06-21 | A porphyrin-chrysin conjugate and its synthesis method and application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN118852182B (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109912607A (en) * | 2018-12-11 | 2019-06-21 | 南华大学 | A class of porphyrin-chrysin complexes and their antitumor activity |
| CN112209939A (en) * | 2020-09-15 | 2021-01-12 | 南华大学 | A kind of porphyrin-chrysin complex containing ester bond and its antitumor activity |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102733396B1 (en) * | 2021-10-21 | 2024-11-25 | 닥터아이앤비(주) | Composition of anticancer agent with photoactive combination therapy and producing method thereof |
-
2024
- 2024-06-21 CN CN202410810674.1A patent/CN118852182B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109912607A (en) * | 2018-12-11 | 2019-06-21 | 南华大学 | A class of porphyrin-chrysin complexes and their antitumor activity |
| CN112209939A (en) * | 2020-09-15 | 2021-01-12 | 南华大学 | A kind of porphyrin-chrysin complex containing ester bond and its antitumor activity |
Also Published As
| Publication number | Publication date |
|---|---|
| CN118852182A (en) | 2024-10-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5591847A (en) | Long wavelength absorbing photosensitizers related to purpurin-18, bacteriopurpurin-18 and related compounds with imide linkages | |
| US6624187B1 (en) | Long wave length absorbing bacteriochlorin alkyl ether analogs | |
| EP1404678B1 (en) | Water-soluble porphyrin derivatives for photodynamic therapy, their use and manufacture | |
| US7169753B2 (en) | Chlorophyll and bacteriochlorophyll esters, their preparation and pharmaceutical compositions comprising them | |
| PT863903E (en) | SYNTHETIC DERIVATIVES OF BACTERIOCLOROFILA SUBSTITUTED BY METAL AND THEIR USE | |
| AU2002312154A1 (en) | Water-soluble porphyrin derivatives for photodynamic therapy, their use and manufacture | |
| US20030023081A1 (en) | Water-soluble porphyrin derivatives for photodynamic therapy, their use and manufacture | |
| CN101569627B (en) | Folic acid acceptor mediated molecular targeted photosensitizer and preparation method thereof | |
| CN109575061B (en) | A kind of water-soluble anticancer photosensitizer and its preparation and application | |
| CN109456352B (en) | Phenylboronic acid ester modified hydrogen peroxide activated type boron dipyrromethene photosensitizer and preparation thereof | |
| CN113831351B (en) | Novel tetrapyrrole derivatives and application thereof | |
| CN102698269A (en) | A kind of zinc phthalocyanine complex and preparation method thereof | |
| CN116554182B (en) | Porphyrin-eugenol derivative, preparation method and application thereof | |
| CN119039304B (en) | A carboxyl porphyrin-curcumin ester conjugate and its preparation method and application | |
| CN116217515A (en) | A compound, its preparation method and its application in detecting cysteine | |
| CN118852182A (en) | A porphyrin-chrysin conjugate and its synthesis method and application | |
| CN116444532B (en) | Porphyrin warfarin derivative and preparation method and application thereof | |
| CN114409687B (en) | Photosensitive medicine capable of switching light treatment modes in tumor and preparation method and application thereof | |
| CN114524822B (en) | Novel intermediate diphenyl naphthoporphin derivative and application thereof in medicine field | |
| CN113278413B (en) | NQO1 near-infrared fluorescent probe based on naphthoquinone trigger group, preparation method and application | |
| CN106083872B (en) | Violet-18 ether derivatives and preparation method and use thereof | |
| RU2772691C1 (en) | Photosensitiser and method for production thereof | |
| RU2707754C1 (en) | Fluorinated porphyrin derivatives exhibiting anti-tumor activity | |
| RU2725876C1 (en) | Derivatives of fluorine-containing chlorins exhibiting anti-tumour activity | |
| CN115960115A (en) | Fluorescein derivative and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |